HSP90 inhibitor antagonizing MIF the specifics of pleiotropic cancer drug candidates

Ramona Schulz; Matthias Dobbelstein; Ute M. Moll

doi:10.4161/onci.21173

HSP90 inhibitor antagonizing MIF the specifics of pleiotropic cancer drug candidates

Ramona Schulz
, Matthias Dobbelstein
, Ute M. Moll

Pathology

Stony Brook University

University of Göttingen

Research output: Contribution to journal › Comment/debate

10 Scopus citations

Abstract

Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite-or perhaps because of-their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2- overexpressing breast cancer.

Original language	English
Pages (from-to)	1425-1426
Number of pages	2
Journal	OncoImmunology
Volume	1
Issue number	8
DOIs	https://doi.org/10.4161/onci.21173
State	Published - 2012

Keywords

Breast cancer
CHIP
Client
HSP90 inhibitors
MIF

Access to Document

10.4161/onci.21173

Cite this

@article{94faf624bbc849a29093baeaac9f66c3,

title = "HSP90 inhibitor antagonizing MIF the specifics of pleiotropic cancer drug candidates",

abstract = "Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite-or perhaps because of-their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2- overexpressing breast cancer.",

keywords = "Breast cancer, CHIP, Client, HSP90 inhibitors, MIF",

author = "Ramona Schulz and Matthias Dobbelstein and Moll, \{Ute M.\}",

year = "2012",

doi = "10.4161/onci.21173",

language = "English",

volume = "1",

pages = "1425--1426",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "8",

}

TY - JOUR

T1 - HSP90 inhibitor antagonizing MIF the specifics of pleiotropic cancer drug candidates

AU - Schulz, Ramona

AU - Dobbelstein, Matthias

AU - Moll, Ute M.

PY - 2012

Y1 - 2012

N2 - Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite-or perhaps because of-their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2- overexpressing breast cancer.

AB - Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite-or perhaps because of-their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an essential HSP90 client protein in a murine model of Her2- overexpressing breast cancer.

KW - Breast cancer

KW - CHIP

KW - Client

KW - HSP90 inhibitors

KW - MIF

UR - https://www.scopus.com/pages/publications/84879418453

U2 - 10.4161/onci.21173

DO - 10.4161/onci.21173

M3 - Comment/debate

SN - 2162-4011

VL - 1

SP - 1425

EP - 1426

JO - OncoImmunology

JF - OncoImmunology

IS - 8

ER -

HSP90 inhibitor antagonizing MIF the specifics of pleiotropic cancer drug candidates

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this